Active Surveillance for Low-Risk PCa: Sprint or Marathon?

Philip Segal and Bruno Barrey were diagnosed with prostate cancer and opted for active surveillance to monitor but not treat the disease. Each has a different approach; Segal, at age 80, plans to maintain the status quo while Barrey, age 57, abandoned active surveillance after six months and opted for radiation therapy, as his cancer progressed. The approach of active surveillance can prove to be a short-term or lifetime strategy with approximately half of men abandoning it within 5 years. Emerging changes include the use of MRI and a decline in screening, impacting the accuracy of staging the disease and the rate of active surveillance dropouts. Urologists disagree on the best approach depending on several factors and individual patients.

Source link

error: Content is protected !!